WINNIPEG, MANITOBA--(Marketwire - September 09, 2008) - Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, is pleased to announce that BioVectra has successfully completed the manufacturing of clinical grade DispersinB™ in their cGMP facility from the Master Cell Bank created earlier this year (July 7th Kane Biotech press release).
